Editas Medicine Inc (EDIT)vsRevolution Medicines Inc (RVMD)
EDIT
Editas Medicine Inc
$2.71
-9.36%
HEALTHCARE · Cap: $415.88M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Editas Medicine Inc generates 5115% more annual revenue ($38.69M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -281.6%. RVMD earns a higher WallStSmart Score of 24/100 (F).
EDIT
Avoid15
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 54.2x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EDIT
EDIT has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : EDIT
The primary concerns for EDIT are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 16.33 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
EDIT profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
EDIT carries more volatility with a beta of 2.10 — expect wider price swings.
EDIT is growing revenue faster at -39.2% — sustainability is the question.
EDIT generates stronger free cash flow (-23M), providing more financial flexibility.
Bottom Line
RVMD scores higher overall (24/100 vs 15/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Editas Medicine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?